Drug Profile


Alternative Names: NW-1029; Priralfinamide

Latest Information Update: 09 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Newron Pharmaceuticals; Purdue Biopharma
  • Developer Newron Pharmaceuticals
  • Class Analgesics; Fluorobenzenes; Small molecules
  • Mechanism of Action Glutamate receptor antagonists; Sodium channel antagonists; Substance P release inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Pain; Psychiatric disorders

Highest Development Phases

  • Phase II/III Neuropathic pain
  • Discontinued Dental pain; Inflammatory pain

Most Recent Events

  • 09 Sep 2015 Phase-II/III development is still ongoing for Neuropathic pain in the EU and India
  • 21 Aug 2012 Discontinued - Phase-II for Dental pain in India (PO)
  • 21 Aug 2012 Discontinued - Phase-II for Dental pain in Romania (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top